Eidelman Virant Capital’s ImmuCell ICCC Stock Holding History

Eidelman Virant Capital’s Portfolio ICCC Stock Details ICCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-14,000	Closed	-$91K	–	128
2019 Q2	$91K	Buy	+14,000	New	+$88.8K	0.05%	119

Other funds holding ICCC

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

PCM

Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return

SRC

Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return

HPC

HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

Eidelman Virant Capital's ICCC Position: Q3 2019 in Review

Eidelman Virant Capital sold out of ImmuCell (ICCC) in Q3 2019, closing a stake of 14,000 shares — an estimated $91K sold.

Eidelman Virant Capital first reported a position in ICCC in Q2 2019 and held it in 1 quarter. The position peaked at $91K in Q2 2019. 22 funds tracked by Wall St. Rank hold ICCC as of Q3 2019.

Eidelman Virant Capital reported no remaining ImmuCell position as of Q3 2019 after selling out during the quarter.
Eidelman Virant Capital sold 14,000 ImmuCell shares in Q3 2019, an estimated $91K.
Eidelman Virant Capital first reported a position in ImmuCell in Q2 2019 and held it in 1 quarter.
Eidelman Virant Capital's ImmuCell position peaked at $91K in Q2 2019.
22 funds tracked by Wall St. Rank held ImmuCell as of Q3 2019.

Based on Eidelman Virant Capital's 13F filing for Q3 2019, filed 29 Oct 2019.